Abstract:It is well-known that the potency of a drug is heavily associated with its kinetic and thermodynamic properties with the target. Nuclear receptors (NRs), as an important target family, play important roles in regulating a variety of physiological processes in vivo. However, it is hard to understand the drug-NR interaction process because of the closed structure of the ligand-binding domain (LBD) of the NR proteins, which apparently hinders the rational design of drugs with controllable kinetic properties. Therefore, understanding the underlying mechanism of the ligand-NR interaction process seems necessary to help NR drug design. However, it is usually difficult for experimental approaches to interpret the kinetic process of drug-target interactions. Therefore, in silico methods were utilized to explore the optimal binding/dissociation pathways of the NR ligands. Specifically, farnesoid X receptor (FXR) is considered here as the target system since it has been an important target for the treatment of bile acid metabolism-associated diseases, and a series of structures cocrystallized with diverse scaffold ligands were resolved. By using random acceleration molecular dynamics (RAMD) simulation and umbrella sampling (US), 5 main dissociation pathways (pathways I-V) were identified in 11 representative FXR ligands, with most of them (9/11) preferring to go through Pathway III and the remaining two favoring escaping from Pathway I and IV. Furthermore, key residues functioning in the three main dissociation pathways were revealed by the kinetic residue energy analysis (KREA) based on the US trajectories, which may serve as road-marker residues for rapid identification of the (un)binding pathways of FXR ligands. Moreover, the preferred pathways explored by RAMD simulations are in good agreement with the minimum free energy path identified by the US simulations with the Pearson R = 0.76 between the predicted binding affinity and the experimental data, suggesting that RAMD is suitable for applying in large-scale (un)binding-pathway exploration in the case of ligands with obscure binding tunnels to the target.

Recognition of LXXLL by ligand binding domain of the Farnesoid X receptor in molecular dynamics simulation

Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Ligand-Dependent Coactivation of the Human Bile Acid Receptor FXR by the Peroxisome Proliferator-Activated Receptor Γ Coactivator-1α

Ligand Binding and Heterodimerization with Retinoid X Receptor Α (rxrα) Induce Farnesoid X Receptor (FXR) Conformational Changes Affecting Coactivator Binding

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Structural Basis of the Farnesoid X Receptor/retinoid X Receptor Heterodimer on Inverted Repeat DNA

Exhaustively Exploring the Prevalent Interaction Pathways of Ligands Targeting the Ligand-Binding Pocket of Farnesoid X Receptor via Combined Enhanced Sampling

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Asymmetric binding of coactivator SRC1 to FXR-RXR and allosteric communication within the complex

Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR

3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists

Nuclear receptor interdomain communication is mediated by the hinge with ligand specificity

Computational Insight into the Allosteric Activation Mechanism of Farnesoid X Receptor

A Novel Class of Natural FXR Modulators with a Unique Mode of Selective Co‐regulator Assembly

Simulations reveal unique roles for the FXR hinge in the FXR-RXR nuclear receptor heterodimer

STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR

Discovery of New Non-Steroidal FXR Ligands Via a Virtual Screening Workflow Based on Phase Shape and Induced Fit Docking

[Progress in the Ligands and Their Complex Structures of Farnesoid X Receptor].

Farnesoid X Receptor (FXR): Structures and Ligands.

Unbinding Pathways of GW4064 from Human Farnesoid X Receptor As Revealed by Molecular Dynamics Simulations.